

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

LS174T

RRID:CVCL_1384

Type: Cell Line

Proper Citation

RRID:CVCL_1384

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1384

Proper Citation: RRID:CVCL_1384

Description: Cell line LS174T is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Colon adenocarcinoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:1262041](#), [PMID:1999484](#), [PMID:3335022](#), [PMID:3349466](#), [PMID:3518877](#), [PMID:3664476](#), [PMID:6401685](#), [PMID:6652615](#), [PMID:6935474](#), [PMID:7370982](#), [PMID:7459858](#), [PMID:7972006](#), [PMID:8422623](#), [PMID:8464898](#), [PMID:8895552](#), [PMID:9000147](#), [PMID:9290701](#), [PMID:9294210](#), [PMID:10674020](#), [PMID:10737795](#), [PMID:11226274](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:11526487](#), [PMID:12068308](#), [PMID:12606785](#), [PMID:15900046](#), [PMID:16418264](#), [PMID:16854228](#), [PMID:18258742](#), [PMID:19132987](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:23272949](#), [PMID:24042735](#), [PMID:24755471](#), [PMID:24840470](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:29101300](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LS174T

Synonyms: Ls174T, LS174t, Ls-174-T, LS-174-T, LS 174 T, LS-174T, Ls-174T, LS 174T, LS-174, LS174, Laboratory of Surgery 174T

Cross References: BTO:BTO_0001553, CLO:CLO_0007393, CLO:CLO_0007403, EFO:EFO_0002227, MCCL:MCC:0000504, CLDB:cl3261, AddexBio:C0009013/379, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ATCC:CCL-188, ATCC:CL-188, BCRC:60053, BioSample:SAMN03470826, BioSample:SAMN03471296, cancercellines:CVCL_1384, CCRID:1101HUM-PUMC000248, CCRID:3101HUMTCHu32, CCRID:4201HUM-CCTCC00135, CCTCC:GDC0135, Cell_Model_Passport:SIDM01200, ChEMBL-Cells:ChEMBL3307536, ChEMBL-Targets:ChEMBL614097, CLS:300392, ColonAtlas:LS174T, Cosmic:711255, Cosmic:719679, Cosmic:724843, Cosmic:738927, Cosmic:873703, Cosmic:875424, Cosmic:876717, Cosmic:887219, Cosmic:889533, Cosmic:907793, Cosmic:934563, Cosmic:948131, Cosmic:948856, Cosmic:985998, Cosmic:995405, Cosmic:1043822, Cosmic:1057755, Cosmic:1066210, Cosmic:1122328, Cosmic:1132565, Cosmic:1132692, Cosmic:1184087, Cosmic:1184334, Cosmic:1187310, Cosmic:1312305, Cosmic:1479573, Cosmic:1486134, Cosmic:1524341, Cosmic:1676738, Cosmic:1708419, Cosmic:1805263, Cosmic:2301546, Cosmic:2301997, Cosmic:2646768, Cosmic:2651866, Cosmic:2668256, Cosmic:2760087, Cosmic:2787546, DSMZ:ACC-759, DSMZCellDive:ACC-759, ECACC:87060401, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM513911, GEO:GSM514297, GEO:GSM741264, GEO:GSM784021, GEO:GSM827345, GEO:GSM1346883, GEO:GSM1374632, GEO:GSM1374633, GEO:GSM1448164, GEO:GSM2550009, IARC_TP53:21478, IARC_TP53:21708, IGRhCellID:LS174T, KCB:KCB 200829YJ, KCLB:10188, LINCS_LDP:LCL-1182, Lonza:1127, MetaboLights:MTBLS227, NCBI_Iran:C568, PharmacDB:LS174T_862_2019, PRIDE:PXD005354, PRIDE:PXD005355, Progenetix:CVCL_1384, PubChem_Cell_line:CVCL_1384, RCB:RCB1961, TKG:TKG 0406, TOKU-E:2235, Ubigene:YC-C088, Wikidata:Q54903053

ID: CVCL_1384

Hierarchy: cvcl_0397

Record Creation Time: 20220427T220735+0000

Record Last Update: 20260905T181044+0000

Ratings and Alerts

No rating or validation information has been found for LS174T.

Warning: Discontinued: RCB; RCB1961

Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line. **Warning:** Discontinued: ATCC; CCL-188

Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 434 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Thorhallsdottir G, et al. (2026) Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot. *Cancer immunology research*, 14(6), 919.

Zheng D, et al. (2026) Oral administration of low-molecular-weight heparin ameliorates colitis by enhancing the gut mucus barrier via microbial tryptophan metabolites. *British journal of pharmacology*, 183(3), 560.

Young TM, et al. (2026) CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. *Cancers*, 18(5).

He H, et al. (2026) L1TD1 promotes colorectal mucinous adenocarcinoma progression by enhancing ABCC3 mRNA stability. *Oncogene*, 45(12), 1071.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE?? with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. *Journal of medicinal chemistry*.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. *Cancer cell*, 44(1), 77.

Sun X, et al. (2026) The Pivotal Role of GR-CAR Pathway in Fetal Programming of Hepatic Cytochrome P450 3A Alteration in Adulthood. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(6), e15583.

Lee CJ, et al. (2026) The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. *Signal transduction and targeted therapy*, 11(1), 19.

Sarkar S, et al. (2026) LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism. *ACS applied bio materials*, 9(4), 1989.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. *Oncology research*, 34(2), 20.

Wang B, et al. (2026) MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis. *Neoplasia (New York, N.Y.)*, 73, 101270.

Behl A, et al. (2026) Activation of an adaptive antitumor immune response by the polymeric fluoropyrimidine CF10 involves TS/Top1 dual targeting. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 199, 119399.

Dohnalov?? K, et al. (2026) Pregnane X receptor antagonist MI-891 reduces hepatic triglycerides in PXR-CAR-CYP3A4/3A7-humanized mice. *Biomedicine & pharmacotherapy* = *Biomedecine & pharmacotherapie*, 197, 119168.

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. *Cell reports*, 45(5), 117338.

Chen Y, et al. (2026) Development of a Highly Effective Bifunctional Ligand 2E-C-NETA for Targeted Lu-177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution. *ChemMedChem*, 21(11), e70325.

Kobayashi H, et al. (2026) A self-amplifying nerve-fibroblast circuit drives colorectal cancer progression. *Cancer cell*.

Ramzy GM, et al. (2025) Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells. *International journal of molecular sciences*, 26(3).

Dusek J, et al. (2025) The hypolipidemic effect of MI-883, the combined CAR agonist/PXR antagonist, in diet-induced hypercholesterolemia model. *Nature communications*, 16(1), 1418.

Dong Z, et al. (2025) The E3 Ligase NEDD4L Prevents Colorectal Cancer Liver Metastasis via Degradation of PRMT5 to Inhibit the AKT/mTOR Signaling Pathway. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(26), e2504704.